Abstract
This is a second part of a review under a main title Antiviral medication in sexually transmitted diseases. In the part we published in Mini Rev Med Chem. 2013,13(13):1837-45, we have described mechanisms of action and mechanism of resistance to antiviral agents used in genital herpes and genital HPV infection. The Part II review focuses on therapeutic options in HIV infection. In 1987, 6 years after the recognition of AIDS, the FDA approved the first drug against HIV - zidovudine. Since then a lot of antiretroviral drugs are available. The most effective treatment for HIV is highly active antiretroviral therapy - a combination of several antiretroviral medicines that cause a reduction of HIV blood concentration and often results in substantial recovery of impaired immunologic function. At present, there are over 20 drugs licensed and used for the treatment of HIV/AIDS, and these drugs are divided into one of six classes. Investigational agents include GS-7340, the prodrug of tenofovir and BMS-663068 - the first in a novel class of drugs that blocks the binding of the HIV gp120 to the CD4 receptor.
Keywords: Antimicrobial resistance, cARV, fusion inhibitors, HAART, human immunodeficiency virus, inhibitors, nucleoside reverse transcriptase, protease inhibitors, sexually transmitted diseases.
Mini-Reviews in Medicinal Chemistry
Title:Antiviral Medication in Sexually Transmitted Diseases. Part II: HIV
Volume: 15 Issue: 2
Author(s): Anna Majewska, Beata Mlynarczyk-Bonikowska, Magdalena Malejczyk, Grazyna Mlynarczyk and Slawomir Majewski
Affiliation:
Keywords: Antimicrobial resistance, cARV, fusion inhibitors, HAART, human immunodeficiency virus, inhibitors, nucleoside reverse transcriptase, protease inhibitors, sexually transmitted diseases.
Abstract: This is a second part of a review under a main title Antiviral medication in sexually transmitted diseases. In the part we published in Mini Rev Med Chem. 2013,13(13):1837-45, we have described mechanisms of action and mechanism of resistance to antiviral agents used in genital herpes and genital HPV infection. The Part II review focuses on therapeutic options in HIV infection. In 1987, 6 years after the recognition of AIDS, the FDA approved the first drug against HIV - zidovudine. Since then a lot of antiretroviral drugs are available. The most effective treatment for HIV is highly active antiretroviral therapy - a combination of several antiretroviral medicines that cause a reduction of HIV blood concentration and often results in substantial recovery of impaired immunologic function. At present, there are over 20 drugs licensed and used for the treatment of HIV/AIDS, and these drugs are divided into one of six classes. Investigational agents include GS-7340, the prodrug of tenofovir and BMS-663068 - the first in a novel class of drugs that blocks the binding of the HIV gp120 to the CD4 receptor.
Export Options
About this article
Cite this article as:
Majewska Anna, Mlynarczyk-Bonikowska Beata, Malejczyk Magdalena, Mlynarczyk Grazyna and Majewski Slawomir, Antiviral Medication in Sexually Transmitted Diseases. Part II: HIV, Mini-Reviews in Medicinal Chemistry 2015; 15 (2) . https://dx.doi.org/10.2174/138955751502150305154459
DOI https://dx.doi.org/10.2174/138955751502150305154459 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
TGF-β Pathway as a Therapeutic Target in Bone Metastases
Current Pharmaceutical Design α-Halogenoacrylic Derivatives of Antitumor Agents
Mini-Reviews in Medicinal Chemistry Tumour Targeting with Systemically Administered Bacteria
Current Gene Therapy The p53-p66Shc Apoptotic Pathway is Dispensable for Tumor Suppression whereas the p66Shc-generated Oxidative Stress Initiates Tumorigenesis
Current Pharmaceutical Design Recent Patents on Nucleic Acid-Based Antiviral Therapeutics
Recent Patents on Anti-Infective Drug Discovery Marine Natural Products and Related Compounds as Anticancer Agents: an Overview of their Clinical Status
Anti-Cancer Agents in Medicinal Chemistry From Small to Powerful: The Fragments Universe and its “Chem-Appeal”
Current Medicinal Chemistry Molecular Mechanisms of Tumor Invasion and Metastasis: An Integrated View
Current Molecular Medicine Evaluating 3D-printed Bolus Compared to Conventional Bolus Types Used in External Beam Radiation Therapy
Current Medical Imaging Multifunctional Proteins in Tumorigenesis: Aminoacyl-tRNA Synthetases and Translational Components
Current Proteomics RNA Metabolism in Neurodegenerative Disease
Current Chemical Biology Epothilone B and its Analogs - A New Family of Anticancer Agents
Mini-Reviews in Medicinal Chemistry Epigenetic Regulation of ABCB1 Transporter Expression and Function
Current Pharmacogenomics and Personalized Medicine Competition Between Tumor and Mononuclear Phagocyte System Causing the Low Tumor Distribution of Nanoparticles and Strategies to Improve Tumor Accumulation
Current Drug Delivery Mitocans: Mitochondrial Targeted Anti-Cancer Drugs as Improved Therapies and Related Patent Documents
Recent Patents on Anti-Cancer Drug Discovery The Potential of Modulating Small RNA Activity In Vivo
Mini-Reviews in Medicinal Chemistry The Clinical Genetics of Psoriasis
Current Genomics Cyanidin 3-O-Glucoside Induces the Apoptosis in the Osteosarcoma Cells through Upregulation of the PPARγ and P21: An <i>In Vitro</i> Study
Anti-Cancer Agents in Medicinal Chemistry Targeting Hypoxia-Inducible Factor-1 (HIF-1) Signaling in Therapeutics: Implications for the Treatment of Inflammatory Bowel Disease
Recent Patents on Inflammation & Allergy Drug Discovery Impact of Primary Tumor Location on First-line Bevacizumab or Cetuximab in Metastatic Colorectal Cancer
Reviews on Recent Clinical Trials